Daniel Gesua Sive Salvadori
Net Worth

Last updated:

What is Daniel Gesua Sive Salvadori net worth?

The estimated net worth of Mr. Daniel Gesua Sive Salvadori is at least $69,075,384 as of 1 Mar 2024. He owns shares worth $16,530,412 as insider, has earned $35,644,972 from insider trading and has received compensation worth at least $16,900,000 in Abbott Laboratories.

What is the salary of Daniel Gesua Sive Salvadori?

Mr. Daniel Gesua Sive Salvadori salary is $1,690,000 per year as Executive Vice President and Group Pres of Established Pharmaceuticals & Nutritional Products in Abbott Laboratories.

How old is Daniel Gesua Sive Salvadori?

Mr. Daniel Gesua Sive Salvadori is 46 years old, born in 1979.

What stocks does Daniel Gesua Sive Salvadori currently own?

As insider, Mr. Daniel Gesua Sive Salvadori owns shares in one company:

Company Title Shares Price per share Total value
Abbott Laboratories (ABT) Executive Vice President and Group Pres of Established Pharmaceuticals & Nutritional Products 125,697 $131.51 $16,530,412

What does Abbott Laboratories do?

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

ABT logo
ABT
Abbott Laboratories
$131.51

Daniel Gesua Sive Salvadori insider trading

Abbott Laboratories

Mr. Daniel Gesua Sive Salvadori has made 24 insider trades between 2015-2024, according to the Form 4 filled with the SEC. Most recently he sold 963 units of ABT stock worth $114,116 on 1 Mar 2024.

The largest trade he's ever made was exercising 96,603 units of ABT stock on 23 Oct 2017. As of 1 Mar 2024 he still owns at least 125,697 units of ABT stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common shares without par value 963 $118.5 $114,116
Sale
Common shares without par value 1,085 $100.7 $109,260
Sale
Common shares without par value 1,550 $118.17 $183,165
Option
Option (right to buy) 23,771 $38.4 $912,806
Option
Option (right to buy) 31,229 $44.4 $1,386,568
Sale
Common shares without par value 58,501 $140 $8,190,140
Option
Common shares without par value 31,229 $44.4 $1,386,568
Option
Common shares without par value 23,771 $38.4 $912,806
Option
Common shares without par value 23,771 $38.4 $912,806
Option
Option (right to buy) 23,771 $38.4 $912,806
Option
Option (right to buy) 31,229 $44.4 $1,386,568
Option
Common shares without par value 31,229 $44.4 $1,386,568
Sale
Common shares without par value 55,000 $135 $7,425,000
Sale
Common shares without par value 1,664 N/A N/A
Sale
Common shares without par value 42,479 $47 $1,996,513
Option
Common shares without par value 42,479 $47 $1,996,513
Option
Option (right to buy) 42,479 $47 $1,996,513
Sale
Common shares without par value 999 $77.89 $77,812
Option
Common shares without par value 71,000 $38.4 $2,726,400
Sale
Common shares without par value 71,000 $38.4 $2,726,400
Option
Option (right to buy) 71,000 $38.4 $2,726,400
Sale
Common shares without par value 3,331 $82 $273,142
Sale
Common shares without par value 7,269 $82 $596,058
Sale
Common shares without par value 1,664 $78 $129,792
Sale
Common shares without par value 5,000 $73.4 $366,980
Sale
Common shares without par value 1,000 $61.5 $61,500
Sale
Common shares without par value 2,000 $61.05 $122,092
Sale
Common shares without par value 905 $58.97 $53,369
Option
Common shares without par value 28,319 $47 $1,330,993
Sale
Common shares without par value 28,319 $54.92 $1,555,223
Option
Option (right to buy) 28,319 $47 $1,330,993
Option
Option (right to buy) 71,157 $38.4 $2,732,429
Option
Common shares without par value 71,157 $38.4 $2,732,429
Sale
Common shares without par value 71,157 $38.4 $2,732,429
Option
Common shares without par value 96,603 $44.54 $4,302,698
Sale
Common shares without par value 96,603 $56.21 $5,430,055
Option
Option (right to buy) 96,603 $43.72 $4,223,483
Option
Option (right to buy) 62,460 $44.54 $2,781,968
Option
Common shares without par value 62,460 $44.54 $2,781,968
Sale
Common shares without par value 62,460 $52.95 $3,307,257
Sale
Common shares without par value 2,066 $45.39 $93,776
Sale
Common shares without par value 815 $41.71 $33,994
Sale
Common shares without par value 881 $39.26 $34,591
Sale
Common shares without par value 815 $39.64 $32,310

Abbott Laboratories key executives

Abbott Laboratories executives and other stock owners filed with the SEC: